Vor Biopharma (NASDAQ:VOR) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research note released on Monday, Marketbeat.com reports. The firm issued a buy rating and a $50.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. TD Cowen began coverage on shares of Vor Biopharma in a report on Wednesday, December 17th. They issued a “buy” rating on the stock. Wells Fargo & Company began coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. reduced their price objective on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Finally, Citigroup began coverage on shares of Vor Biopharma in a report on Friday, January 9th. They issued a “buy” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $49.89.

Vor Biopharma Stock Up 1.5%

VOR opened at $14.70 on Monday. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The firm has a market capitalization of $153.03 million, a P/E ratio of -0.04 and a beta of 1.99. The firm’s 50 day moving average is $14.19 and its 200-day moving average is $17.85.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in Vor Biopharma during the fourth quarter valued at $229,000. Susquehanna Portfolio Strategies LLC acquired a new stake in Vor Biopharma during the 4th quarter worth about $134,000. Tudor Investment Corp ET AL purchased a new position in Vor Biopharma during the 4th quarter valued at about $2,193,000. Sphera Funds Management LTD. purchased a new position in Vor Biopharma during the 4th quarter valued at about $5,368,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Vor Biopharma in the 4th quarter valued at about $350,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).